Literature DB >> 20561330

The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology.

Siok Swan Tan1, Chantal W M Van Gils, Margreet G Franken, Leona Hakkaart-van Roijen, Carin A Uyl-de Groot.   

Abstract

OBJECTIVES: Many economic evaluations are conducted in the fields of oncology and hematology, partially owing to the introduction of new expensive drugs in this field. Even though inpatient days, outpatient visits, and daycare treatments are frequently the main drivers of total treatment costs, their unit costs often lack generalizability. Therefore, we aimed to determine the unit costs of inpatient hospital days, outpatient visits, and daycare treatments specifically for oncological and hematological diseases in The Netherlands from the hospital's perspective.
METHODS: Unit costs were collected from 30 oncological and hematological departments of 6 university and 24 general hospitals. Costs included direct labor and indirect labor, hotel and nutrition, overheads and capital. Ordinary least squares regression models were constructed to examine the degree of association between unit costs and hospital and hospital department characteristics. All costs were based on Euro 2007 cost data.
RESULTS: At university hospitals, the unit costs per inpatient day were determined at €633 in oncological and €680 in hematological departments. At general hospitals, the mean costs per inpatient day were €400. Unit costs for inpatient hospital days, outpatient visits. and daycare treatments equalled the relative ratio 100:21:44. Direct labor costs were the major cost driver and the type of hospital (university, yes/no) was a strong predictor of unit costs.
CONCLUSIONS: The present study provided unit costs for inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. The results may be used as Dutch reference unit prices in economic evaluations assessing oncological and hematological diseases.
© 2010, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Entities:  

Mesh:

Year:  2010        PMID: 20561330     DOI: 10.1111/j.1524-4733.2010.00740.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  6 in total

1.  Real-world cost-effectiveness of oxaliplatin in stage III colon cancer: a synthesis of clinical trial and daily practice evidence.

Authors:  Chantal W M van Gils; Saskia de Groot; William K Redekop; Miriam Koopman; Cornelis J A Punt; Carin A Uyl-de Groot
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

2.  Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck.

Authors:  N van der Linden; C W M van Gils; C P Pescott; J Buter; M R Vergeer; C A Uyl-de Groot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-19       Impact factor: 2.503

3.  Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands.

Authors:  Naomi van der Linden; Jan Buter; Chris P Pescott; Roy I Lalisang; Jan Paul de Boer; Alexander de Graeff; Carla M L van Herpen; Robert J Baatenburg de Jong; Carin A Uyl-de Groot
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-01-21       Impact factor: 2.503

4.  Mapping nurses' activities in surgical hospital wards: A time study.

Authors:  W F J M van den Oetelaar; H F van Stel; W van Rhenen; R K Stellato; W Grolman
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

5.  Hospital unit costs in Jordan: insights from a country facing competing health demands and striving for universal health coverage.

Authors:  Eman A Hammad; Ibrahim Alabbadi; Fardos Taissir; Malek Hajjwi; Nathir M Obeidat; Qais Alefan; Rimal Mousa
Journal:  Health Econ Rev       Date:  2022-02-05

6.  Using a Patient Hotel: Perceptions of the Quality of Care by Patients Undergoing Analysis for Gastrointestinal Motility Disorders in the Netherlands.

Authors:  Gwen Mc Masclee; Ad Am Masclee; Joanna W Kruimel; José M Conchillo; Jedidja van Vliet; Daniel Keszthelyi
Journal:  J Patient Exp       Date:  2022-03-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.